Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT) Genetics Study

Mary Jeanne Kreek, MD
Lead Investigator

Rockefeller University, Kreek Lab

This ancillary study is related to CTN-0051, "Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT)."

This study will examine functional variants in three genes (OPRM1, OPRK1, and PDYN) known to affect the dynamic response to opioid receptor ligands. These variants will be evaluated for their contribution to treatment retention, abstinence, and depression in the CTN-0051 trial. Their effects will be compared between the two alternative treatments: extended-release injectable naltrexone (XR-NTX) and buprenorphine-naloxone (BUP-NX). Pharmacogenomics application of study results obtained may allow individual tailoring of these medications. In addition, knowledge pertaining to other aspects of pathophysiology of the receptors systems targeted by XR-NTX or BUP-NX may be gained.





Publications about CTN-0051-A-1

Greater New York (Lead) search www
  Bellevue Hospital Center search www
Mid-Atlantic search www
  Avery Road Treatment Center search www
Florida Node Alliance search www
Gateway Community Services search www
New England Consortium search www
SSTAR of Massachusetts search www
Ohio Valley search www
Maryhaven, Inc. search www
Pacific Northwest search www
  Evergreen Treatment Services search www
Pacific Region search www
Tarzana Treatment Center search www
Southwest search www
Turquoise Lodge Hospital search www

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 11/2016 --